What's the new normal for global oil?

What you'll learn

• 1 (01:22) **U.S. Oil Hits $100 as Middle East Disruptions Create a "New Normal"** - American crude loses its usual price insulation, spiking over $100 a barrel alongside global Brent crude, driven by a 65% drop in Middle East oil shipments and the expectation that Iran can and will block the Strait of Hormuz.
• 2 (04:39) **August PPI Surges on Higher Energy, Fueling Transportation Inflation** - The producer price index rose 0.4% in August, driven almost entirely by energy costs, which are now pushing up the cost of trucking and warehousing by over 14% year-over-year.
• 3 (06:06) **Businesses Face a Dilemma: Pass on Higher Costs or Lose Customers** - While some companies can pass higher transportation costs to consumers, others, like a fig paste supplier, find their customers pushing back hard to avoid losing price-sensitive grocery shoppers.
• 4 (07:21) **The Enduring Tariff Burden: A Queens Business Owner's Frustration** - Despite the U.S.-Canada trade war dominating headlines, the average tariff on all other imports remains at 11%, creating a bureaucratic nightmare for small businesses like Death by Audio, which is owed nearly $100,000 in tariff refunds.
• 5 (12:16) **Targeted Solar Tariffs Aim to Rebuild U.S. Manufacturing, But at a High Cost** - The Trump administration's new tariffs on polysilicon are designed to protect U.S. solar manufacturers like Q Cells, which has invested $2.5 billion in a massive Georgia factory to bring the entire supply chain under one roof for the first time in years.
• 6 (16:52) **Market Numbers: Stocks Fall, Transport Flat, Yields Rise** - The Dow fell 316 points, the NASDAQ dropped over 6/10ths of a percent, and the yield on the 10-year Treasury note rose to 4.95%, while trucking stocks like J.B. Hunt and Old Dominion Freight Line were flat to slightly down.
• 7 (19:50) **AI Could Revolutionize Drug Discovery, But Creates a Testing Bottleneck** - Anthropic's new Claude Science tool can identify drug candidates much faster than humans, but the long, expensive FDA clinical trial process could become a major bottleneck for all the new ideas.

+ Full timestamped outline available in the app